[1]秦焕蓉,吴祥锴,江哲宇,等.微小核糖核酸-155对肝癌细胞增殖、侵袭迁移和凋亡的影响[J].介入放射学杂志,2024,33(01):44-51.
 QIN Huanrong,WU Xiangkai,JIANG Zheyu,et al.The effect of microRNA-155 on the proliferation, invasion, migration and apoptosis of hepatocellular carcinoma cells[J].journal interventional radiology,2024,33(01):44-51.
点击复制

微小核糖核酸-155对肝癌细胞增殖、侵袭迁移和凋亡的影响()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年01
页码:
44-51
栏目:
实验研究
出版日期:
2024-01-31

文章信息/Info

Title:
The effect of microRNA-155 on the proliferation, invasion, migration and apoptosis of hepatocellular carcinoma cells
作者:
秦焕蓉 吴祥锴 江哲宇 张 赟 林丽云 王黎洲 周 石
Author(s):
QIN Huanrong WU Xiangkai JIANG Zheyu ZHANG Yun LIN Liyun WANG Lizhou ZHOU Shi.
School of Medical Imaging, Guizhou Medical University, Guiyang, Guizhou Province 550004, China
关键词:
【关键词】 肝癌微小核糖核酸-155蛋白酪氨酸磷酸酶非受体21型磷脂酰肌醇3-激酶蛋白激酶B
文献标志码:
A
摘要:
【摘要】 目的 探究微小核糖核酸(miR)- 155靶向蛋白酪氨酸磷酸酶非受体21型(PTPN21)调控磷脂酰肌醇3- 激酶(PI3K)/蛋白激酶B(AKT)信号通路对肝癌细胞增殖、迁移、侵袭的影响。方法 体外培养Huh7人肝癌细胞并通过miR- 155沉默慢病毒(sh- miR- 155)转染下调miR- 155。实时荧光定量聚合酶链反应(RT- qPCR)检测Huh7细胞miR- 155沉默效果,获得稳转细胞株后将细胞株随机分为:Blank组(正常Huh7细胞)、shNC组(Huh7细胞+miR- 155空载体)、sh- miR- 155组(Huh7细胞+miR- 155沉默)、sh- miR- 155+Recilisib组(Huh7细胞+miR- 155沉默+PI3K- AKT激动剂)、shNC+Recilisib组(Huh7细胞+miR- 155空载体+PI3K- AKT激动剂)。双荧光素酶实验检测PTPN21 是否为miR- 155的下游;溴化噻唑蓝四氮唑(MTT)法检测各组细胞增殖能力;流式细胞术测定各组细胞凋亡水平;Transwell实验分析各组细胞侵袭与迁移能力;蛋白质印迹检测各组PTPN21、通路相关蛋白PI3K、P- PI3K、AKT、P- AKT及凋亡相关蛋白BAX、BCL- 2、Caspase- 3表达变化差异。结果 sh- miR- 155组中miR- 155的表达水平低于Blank组及shNC组(P<0.000 1), miR- 155在Blank组及shNC组表达水平差异无统计学意义(P>0.05)。MTT结果显示,sh- miR- 155组中Huh7细胞在2、3、4、5 d时A值均低于Blank组及shNC组(P<0.000 1),而Blank组与shNC组差异无统计学意义(P>0.05);sh- miR- 155组在2、3、4、5 d时A值低于sh- miR- 155+Recilisib组及shNC+Recilisib组(P=0.005 2, P<0.000 1),而sh- miR- 155+Recilisib组在2、3、4、5 d时A值低于shNC+Recilisib组(P<0.000 1)。Blank组与shNC组迁移及侵袭细胞数差异无统计学意义(P>0.05),激活PI3K- AKT信号通路后,与Blank组相比,shNC+Recilisib组肝癌细胞的迁移、侵袭能力显著增加(P<0.000 1)。相反,沉默miR- 155后Huh7细胞的迁移及侵袭细胞数明显低于Blank组及shNC组(P<0.000 1),而PI3K激动剂逆转了这一现象,与sh- miR- 155组相比,sh- miR- 155+Recilisib组肝癌细胞的迁移、侵袭能力增强(P=0.000 2)。慢病毒转染Huh7人肝癌细胞以沉默miR- 155,下调miR- 155抑制PTPN21调控PI3K- AKT信号通路从而抑制肝癌细胞的侵袭、迁移、增殖能力,促进肝癌细胞凋亡。结论 miR- 155通过靶向PTPN21调控PI3K- AKT信号通路抑制肝癌细胞的迁移、侵袭、增殖。miR- 155可能是未来肝癌治疗潜在靶点。

参考文献/References:

[1] Zucman- Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149: 1226- 1239.
[2] 杨 鹏,何 洋,李 成,等. 微小核糖核酸- 7调控表皮细胞生长因子受体对肝癌细胞增殖和转移的影响[J]. 介入放射学杂志, 2021, 30:43- 47.
[3] Liu J, Fan L, Yu H, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR- 23a- 3p and up- regulate programmed death ligand 1 expression in macrophages[J]. Hepatology, 2019, 70: 241- 258.
[4] Santos DAR, Gaiteiro C, Santos M, et al. MicroRNA biomarkers as promising tools for early colorectal cancer screening: a comprehensive review[J]. Int J Mol Sci, 2023, 24: 11023.
[5] Chen S, Wang Y, Li D, et al. Mechanisms controlling microRNA expression in tumor[J]. Cells, 2022, 11: 2852.
[6] Wang J, Wang Q, Guan Y, et al. Breast cancer cell- derived microRNA- 155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function[J]. J Clin Invest, 2022, 132: e157248.
[7] Fang H, Shuang D, Yi Z, et al. Up- regulated microRNA- 155 expression is associated with poor prognosis in cervical cancer patients[J]. Biomed Pharmacother, 2016, 83: 64- 69.
[8] Fu X, Wen H, Jing L, et al. MicroRNA- 155- 5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway[J]. Cancer Sci, 2017, 108: 620- 631.
[9] 王 奕,韩 涛,张志强,等. 血清微小核糖核酸- 599与肝细胞肝癌TACE治疗预后的相关性[J]. 介入放射学杂志, 2021,30:1265- 1270.
[10] Zhang Y, Li X, Zhang Y, et al. Pegylated interferon- α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR- 155[J]. Ann Hepatol, 2019, 18: 494- 500.
[11] Eldosoky MA, Hammad R, Elmadbouly AA, et al. Diagnostic significance of hsa- miR- 21- 5p, hsa- miR- 192- 5p, hsa- miR- 155- 5p, hsa- miR- 199a- 5p panel and ratios in hepatocellular carcinoma on top of liver cirrhosis in HCV- infected patients[J]. Int J Mol Sci, 2023, 24: 3157.
[12] Basova P, Pesta M, Sochor M, et al. Prediction potential of serum miR- 155 and miR- 24 for relapsing early breast cancer[J]. Int J Mol Sci, 2017, 18: 2116.
[13] Guan C, Yang F, He X, et al. Clinical significance of microRNA- 155 expression in hepatocellular carcinoma[J]. Oncol Lett, 2016, 11: 1574- 1580.
[14] Wang CC, Shen WJ, Anuraga G, et al. Novel potential therapeutic targets of PTPN families for lung cancer[J]. J Pers Med, 2022, 12: 1947.
[15] Carlucci A, Porpora M, Garbi C, et al. PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells[J]. J Biol Chem, 2010, 285: 39260- 39270.
[16] Plani- Lam JH, Chow TC, Fan YH, et al. High expression of PTPN21 in B- cell non- Hodgkin’s gastric lymphoma, a positive mediator of STAT5 activity[J]. Blood Cancer J, 2016, 6: e388.
[17] Han W, Wang N, Kong R, et al. Ligand- activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K- AKT signaling pathway[J]. J Transl Med, 2022, 20: 86.
[18] Ghafouri- Fard S, Abak A, Tondro Anamag F, et al. The emerging role of non- coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process[J]. Biomed Pharmacother, 2021, 137: 111279.
[19] Rahmani F, Ziaeemehr A, Shahidsales S, et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma[J]. J Cell Physiol, 2020, 235: 4146- 4152.
[20] 吴佳明, 邓忠权, 朱 奕, 等. MicroRNA- 431- 5p在胃癌组织中低表达:基于线粒体和Bax/Bcl- 2/caspase 3信号通路[J]. 南方医科大学学报, 2023, 43: 537- 543.
[21] Li XQ, Liu BC, Jiang XB, et al. Inhibition of PTPN21 has antitumor effects in glioma by restraining the EGFR/PI3K/AKT pathway[J]. Toxicol Appl Pharmacol, 2022, 451: 116180.

相似文献/References:

[1]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(01):968.
[2]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
 AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(01):1010.
[3]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
 DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(01):75.
[4]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
 ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(01):78.
[5]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗30例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
 ,,et al.TACE combined with radiofrequency ablation for massive primary hepatocellular carcinomas: a clinical therapeutic evaluation [J].journal interventional radiology,2012,(01):322.
[6]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
 .The volume of Lipiodol used in TACE: its current situation and research progress [J].journal interventional radiology,2012,(01):348.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
 HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(01):682.
[8]冉 琳,任伯绪. 125I粒子组织间近距离放射治疗肝癌的现状与进展[J].介入放射学杂志,2012,(10):876.
 RAN Lin,REN Bo- xu.. 125I radioactive seeds brachytherapy for hepatocellular carcinomas: its present situation and research progress[J].journal interventional radiology,2012,(01):876.
[9]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
 LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(01):1035.
[10]徐光如,张明辉,朱红星,等.磁共振ADC值评价肝硬化合并肝癌介入治疗后肝功能储备的初步研究[J].介入放射学杂志,2013,(01):36.
 XU Guang? ru,ZHANG Ming? hui,ZHU Hong? xing,et al. The application of MR?蛳 ADC value in evaluating the liver function reserve in patients with cirrhosis complicated by hepatic cancer after interventional treatment: a preliminary study[J].journal interventional radiology,2013,(01):36.

备注/Memo

备注/Memo:
 (收稿日期:2023- 07- 03)
(本文编辑:新 宇)
更新日期/Last Update: 2024-01-30